{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:40:27Z","timestamp":1759452027025,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2023.03.013","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T16:49:11Z","timestamp":1679417351000},"page":"2739-2742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity of partial doses of live oral cholera vaccine CVD 103-HgR in children in the United States"],"prefix":"10.1016","volume":"41","author":[{"given":"James M.","family":"McCarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cassie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Bedell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.013_b0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QCO.0000000000000474","article-title":"Cholera: recent updates","volume":"31","author":"Weil","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.013_b0010","doi-asserted-by":"crossref","first-page":"e0003832","DOI":"10.1371\/journal.pntd.0003832","article-title":"Updated global burden of cholera in endemic countries","volume":"9","author":"Ali","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.03.013_b0015","unstructured":"Global Task Force on Cholera Control (GTFCC). Ending cholera: a global roadmap to 2030. https:\/\/www.gtfcc.org\/wp-content\/uploads\/2019\/10\/gtfcc-ending-cholera-a-global-roadmap-to-2030.pdf (Accessed 22 Sept 2022)."},{"key":"10.1016\/j.vaccine.2023.03.013_b0020","first-page":"777","article-title":"The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients","volume":"38","author":"Mosley","year":"1968","journal-title":"Bull World Health Organ"},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.013_b0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/143.6.818","article-title":"Duration of infection- derived immunity to cholera","volume":"143","author":"Levine","year":"1981","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.013_b0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/CVI.00601-13","article-title":"Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR prepared from new master and working cell banks","volume":"21","author":"Chen","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2023.03.013_b0035","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.013_b0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.vaccine.2017.12.062","article-title":"Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18\u201345","volume":"36","author":"McCarty","year":"2018","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2023.03.013_b0045","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.vaccine.2019.01.077","article-title":"Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial","volume":"37","author":"McCarty","year":"2019","journal-title":"Vaccine"},{"issue":"8821","key":"10.1016\/j.vaccine.2023.03.013_b0050","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0140-6736(92)92231-4","article-title":"Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children","volume":"340","author":"Suharyono","year":"1992","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2023.03.013_b0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0020-2452(96)85758-7","article-title":"Live oral cholera vaccine: from principle to product","volume":"93","author":"Levine","year":"1995","journal-title":"Bull Inst Pasteur"},{"issue":"7","key":"10.1016\/j.vaccine.2023.03.013_b0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00006454-199907000-00011","article-title":"Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers","volume":"18","author":"Lagos","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.013_b0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4269\/ajtmh.19-0241","article-title":"Safety and immunogenicity of live oral cholera vaccine CVD 103-HgR in children and adolescents aged 6\u201317 years","volume":"102","author":"McCarty","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2023.03.013_b0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4269\/ajtmh.20-0917","article-title":"Safety and immunogenicity of live oral cholera vaccine CVD 103-HgR in children aged 2\u20135 years in the United States","volume":"104","author":"McCarty","year":"2021","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"10.1016\/j.vaccine.2023.03.013_b0080","doi-asserted-by":"crossref","first-page":"e00098","DOI":"10.1128\/CVI.00098-17","article-title":"Antibody-based correlates of protection against cholera: analysis of a challenge study in a cholera- na\u00efve population","volume":"24","author":"Haney","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.03.013_b0075","first-page":"277","article-title":"Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique","volume":"38","author":"Benenson","year":"1968","journal-title":"Bull World Health Organ"},{"issue":"20","key":"10.1016\/j.vaccine.2023.03.013_b0095","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2018.04.011","article-title":"Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection","volume":"36","author":"Haney","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.03.013_b0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14760584.2017.1291348","article-title":"PaxVax CVD 103-HgR single-dose live oral cholera vaccine","volume":"16","author":"Levine","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.013_b0085","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijpharm.2017.08.088","article-title":"Assessment of swallowability and palatability of oral dosage forms in children: Report from an M-CERSI pediatric formulation workshop","volume":"536","author":"Ternik","year":"2018","journal-title":"Int J of Pharm"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.013_b0090","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4269\/ajtmh.21-1317","article-title":"Development of pediatric dosage preparation for CVD 103-HgR live oral cholera vaccine","volume":"107","author":"Duffin","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.03.013_b0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000129624","article-title":"Determinants of responses to oral vaccines in developing countries","volume":"66","author":"Sack","year":"2008","journal-title":"Ann Nestle [Engl]"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:26:04Z","timestamp":1759404364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X23002608"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of partial doses of live oral cholera vaccine CVD 103-HgR in children in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}